Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was among Jim Cramer’s recent stock calls on Mad Money. During the ...

Importantly, it could work for all CF patients, whereas Vertex Pharmaceuticals' medicines target only those with certain ...

As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $441.20, moving +1.27% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.2%. Meanwhile, the Dow ...

Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments.

As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. After ...

Vertex’s type 1 diabetes cell therapy turned heads when one patient's islet cell function was restored. Now, the pharma is readying version 2.0 for the clinic after the FDA cleared a similar treatment ...

Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that it will release first quarter 2026 financial results before the market ...